Authors
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Risk-Based Monitoring Versus Source Data VerificationPilot study compares a risk-based monitoring and remote trial management method with traditional on-site source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
Risk-Based Monitoring Versus Source Data VerificationPilot study compares a risk-based monitoring and remote trial management method with traditional on-site source data verification for trial oversight.
Latest:
Comparing Risk Based Monitoring and Remote Trial Management vs. SDVA new RBM method used in PaxVax trial proves successful vs. onsite source data verification for trial oversight.
Latest:
The Evolving Relationship Between Sponsors and Contract Research OrganizationsIf the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at ICON, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.
Latest:
Human Centered Design—A Pathway to Patient CentricityuMotif worked with IDEO to shape a patient-centric approach by focusing on human-centered design.
Latest:
Patient Centricity: The Journey MattersFive proactive steps industry can take to optimize a patient's clinical trial experience.
Latest:
Alzheimer’s Clinical Trials: Obstacles and OpportunitiesFor sponsors who are pursuing the goal of treating Alzheimer’s disease, understanding the obstacles inherent in Alzheimer’s clinical trials can help in planning for, and overcoming, these challenges.
Latest:
A Roadmap to Phase I Challenges for Cell and Gene Therapy ProductsCell and gene therapies are the latest wave of advanced technologies that will shape the face of the modern-day biopharma arena, enabling a path to pinpoint a faulty gene or cellular mechanism at the root of a specific disease.
Latest:
A Roadmap to Phase I Challenges for Cell and Gene Therapy ProductsCell and gene therapies are the latest wave of advanced technologies that will shape the face of the modern-day biopharma arena, enabling a path to pinpoint a faulty gene or cellular mechanism at the root of a specific disease.
Latest:
A Roadmap to Phase I Challenges for Cell and Gene Therapy ProductsCell and gene therapies are the latest wave of advanced technologies that will shape the face of the modern-day biopharma arena, enabling a path to pinpoint a faulty gene or cellular mechanism at the root of a specific disease.
Latest:
A Roadmap to Phase I Challenges for Cell and Gene Therapy ProductsCell and gene therapies are the latest wave of advanced technologies that will shape the face of the modern-day biopharma arena, enabling a path to pinpoint a faulty gene or cellular mechanism at the root of a specific disease.
Latest:
A United Front for Better Pediatric Clinical TrialsForming strategic alliances and collaborating to optimize study design can significantly improve pediatric drug development.
Latest:
A United Front for Better Pediatric Clinical TrialsForming strategic alliances and collaborating to optimize study design can significantly improve pediatric drug development.
Latest:
3 Key Steps for Building a Successful Research Billing Compliance ProcessBuilding an accurate and consistent billing compliance process is a complex task.
Latest:
Improved Understanding of Psoriasis Buoys Treatment Hopes for PatientsAdvances in our understanding of the genetic, immunological, and environmental factors that contribute to the pathogenesis of psoriasis have led to the development of very effective precision therapies that alleviate patient morbidity and improve quality of life, especially for patients with moderate to severe disease.
Latest:
A Look at Sample and Laboratory Data Management TechnologiesWhat technologies ease clinical trial laboratory sample and data management, and what are the benefits?
Latest:
A Look at Sample and Laboratory Data Management TechnologiesWhat technologies ease clinical trial laboratory sample and data management, and what are the benefits?
Latest:
A Look at Sample and Laboratory Data Management TechnologiesWhat technologies ease clinical trial laboratory sample and data management, and what are the benefits?
Latest:
Developing a Logical Sourcing StrategyThe four essential steps to ensuring optimal clinical deliverable specifications and process controls.
Latest:
Outside-In: Why Putting Patients at the Heart of Drug Development MattersThis article delves into the why, when, and how a patient-centric approach should be adopted for both the benefit of patients and the successful development of novel and innovative medicines.
Latest:
Outside-In: Why Putting Patients at the Heart of Drug Development MattersThis article delves into the why, when, and how a patient-centric approach should be adopted for both the benefit of patients and the successful development of novel and innovative medicines.
Latest:
Trends in Global Public and Patient Perceptions of Clinical ResearchTo inform our understanding of public and patient trust and confidence, this article provides a high-level summary of the results of two studies monitoring trends in international public and patient attitudes and perceptions.
